Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2021-04-07 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-04-07 English
FORM 4
Director's Dealing
2021-04-07 English
FORM 4
Director's Dealing
2021-04-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically announces the date and details of the upcoming Annual Meeting of Stockholders, including the record date and deadlines for stockholder proposals and nominations. It does not contain financial statements or detailed financial performance data, nor is it a proxy statement or the actual annual meeting materials. It is an announcement of an event related to governance and shareholder meetings but does not itself constitute AGM materials or proxy solicitation. Given the nature of the filing and its content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-03-30 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 30, 2021, reporting the issuance of a press release announcing financial results for the quarter and year ended December 31, 2020. The text explicitly states that the press release is furnished as an exhibit and that the information is being furnished, not filed, indicating this is a current report announcing financial results rather than the full financial report itself. The document length is 3379 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. Therefore, this document corresponds to an Earnings Release (ER).
2021-03-30 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. It includes details about the number of shares registered, the equity incentive plan, and legal and indemnification information. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2021-03-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.